Allergic rhinitis (AR) is one of the most common allergic diseases. Achievement of AR control is a priority goal of the disease’s treatment.

OBJECTIVE

To analyze the effectiveness of combined use of intranasal glucocorticosteroids (InGCs) and intranasal antihistamines (InAHs) or systemic antihistamine drugs (sAHDs) In patients with moderate AR and to substantiate the need for a differentiated approach to the choice of pathogenetic drug therapy agents for the disease.

PATIENTS AND METHODS

During the study 47 patients with moderate AR were examined and divided into 2 groups: patients of the 1^st group used a fixed combination of InGCs/InAHs, patients of the 2^nd group — a free combination of InGCs and second-generation sAHDs. The visual analogue scale, total nasal (TNSS) and ocular symptom (TOSS) score scales were used to assess treatment effectiveness. Quality of life evaluation was carried out using the SNOT-22 questionnaire. The method of anterior active rhinomanometry was used in order to objectify the parameters of the nasal patency.

RESULTS

The positive effect of therapy was observed in both groups based on the obtained data. Control of AR, according to the VAS, was achieved in patients from both groups as well. However, a statistically significant improvement by the objective parameters of nasal breathing function has been noted only in patients of the 2^nd group, which can be explained by the presence of intranasal deformities in the vast majority of examined (73 and 95% of patients. respectively) and the systemic action of the sAHDs used per os.

CONCLUSIONS

The revealed structural deformities of the nasal cavity in patients with AR are essential in choosing the means of pathogenetic therapy, and the preferred treatment option in this case may be a free combination of InGCs and sAHDs II.